Hepatitis C in Transplant Recipients of Solid Organs, Other than Liver

Clinics in Liver Disease

Volumn 10, Issue 4, 2006, Pages 901-917

  Wells, Jennifer T ^a   Lucey, Michael R ^a   Said, Adnan ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYCLOSPORIN; ERYTHROPOIETIN; INTERFERON; IRON; METHYLPREDNISOLONE; PEGINTERFERON; PEGINTERFERON ALPHA2B; RIBAVIRIN; TACROLIMUS;

ACUTE KIDNEY FAILURE; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG MONITORING; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HEART GRAFT; HEMOLYSIS; HEPATITIS C; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION; INTESTINE TRANSPLANTATION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY GRAFT; KIDNEY PANCREAS TRANSPLANTATION; LUNG TRANSPLANTATION; NONHUMAN; ORGAN DONOR; ORGAN TRANSPLANTATION; PANCREAS TRANSPLANTATION; PREVALENCE; PROSPECTIVE STUDY; REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

DISEASE TRANSMISSION, HORIZONTAL; GRAFT SURVIVAL; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS;

EID: 33845348937     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2006.08.025     Document Type: Review

References (68)

1. Alter M.J., Kruszon-Moran D., Nainan O.V., et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341 8 (1999) 556-562
2. United Network for Organ Sharing. Available at: http://www.unos.org/data/. Accessed August 16, 2006.
3. Fabrizi F., Poordad F.F., and Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology 36 1 (2002) 3-10
4. Bukh J., Wantzin P., Krogsgaard K., et al. High prevalence of hepatitis C virus (HCV) RNA in dialysis patients: failure of commercially available antibody tests to identify a significant number of patients with HCV infection. Copenhagen Dialysis HCV Study Group. J Infect Dis 168 6 (1993) 1343-1348
5. Hinrichsen H., Leimenstoll G., Stegen G., et al. Prevalence and risk factors of hepatitis C virus infection in haemodialysis patients: a multicentre study in 2796 patients. Gut 51 3 (2002) 429-433
6. Fissell R.B., Bragg-Gresham J.L., Woods J.D., et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int 65 6 (2004) 2335-2342
7. Donahue J.G., Munoz A., Ness P.M., et al. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med 327 6 (1992) 369-373
8. Knudsen F., Wantzin P., Rasmussen K., et al. Hepatitis C in dialysis patients: relationship to blood transfusions, dialysis and liver disease. Kidney Int 43 6 (1993) 1353-1356
9. De Vos J.Y., Elseviers M., Harrington M., et al. Infection control practice across Europe: results of the EPD. EDTNA ERCA J 32 1 (2006) 38-41
10. Lombardi M., Cerrai T., Geatti S., et al. Results of a national epidemiological investigation of HCV infection in dialysis patients. EDTNA ERCA J 25 3 (1999) 38-42
11. Honaker M.R., Stratta R.J., Lo A., et al. Impact of hepatitis C virus status in pancreas transplantation: a case controlled study. Clin Transplant 16 4 (2002) 243-251
12. Fagiuoli S., Minniti F., Pevere S., et al. HBV and HCV infections in heart transplant recipients. J Heart Lung Transplant 20 7 (2001) 718-724
13. Cotler S.J., Jensen D.M., and Kesten S. Hepatitis C virus infection and lung transplantation: a survey of practices. J Heart Lung Transplant 18 5 (1999) 456-459
14. Abbott K.C., Lentine K.L., Bucci J.R., et al. The impact of transplantation with deceased donor hepatitis C-positive kidneys on survival in wait-listed long-term dialysis patients. Am J Transplant 4 12 (2004) 2032-2037
15. File E., Mehra M., Nair S., et al. Allograft transmission of hepatitis C virus infection from infected donors in cardiac transplantation. Transplantation 76 7 (2003) 1096-1100
16. Gudmundsson G.S., Malinowska K., Robinson J.A., et al. Five-year follow-up of hepatitis C-naive heart transplant recipients who received hepatitis C-positive donor hearts. Transplant Proc 35 4 (2003) 1536-1538
17. Hartwig M.G., Patel V., Palmer S.M., et al. Hepatitis B core antibody positive donors as a safe and effective therapeutic option to increase available organs for lung transplantation. Transplantation 80 3 (2005) 320-325
18. Hu K.Q., Lee S.M., Hu S.X., et al. Clinical presentation of chronic hepatitis C in patients with end-stage renal disease and on hemodialysis versus those with normal renal function. Am J Gastroenterol 100 9 (2005) 2010-2018
19. Meyers C.M., Seeff L.B., Stehman-Breen C.O., et al. Hepatitis C and renal disease: an update. Am J Kidney Dis 42 4 (2003) 631-657
20. Boletis J., Delladetsima J., Psimenou E., et al. Liver biopsy is essential in anti-HCV (+) renal transplant patients irrespective of liver function tests and serology for HCV. Transplant Proc 27 1 (1995) 945-947
21. Schroeter M., Zoellner B., Polywka S., et al. Prolonged time until seroconversion among hemodialysis patients: the need for HCV PCR. Intervirology 48 4 (2005) 213-215
22. Alter M.J., Kuhnert W.L., and Finelli L. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention. MMWR Recomm Rep 52 RR-3 (2003) 1-13 15 [quiz CE1-4]
23. Okuda K., and Yokosuka O. Natural history of chronic hepatitis C in patients on hemodialysis: case control study with 4-23 years of follow-up. World J Gastroenterol 10 15 (2004) 2209-2212
24. Stehman-Breen C.O., Emerson S., Gretch D., et al. Risk of death among chronic dialysis patients infected with hepatitis C virus. Am J Kidney Dis 32 4 (1998) 629-634
25. Espinosa M., Martin-Malo A., Alvarez de Lara M.A., et al. Risk of death and liver cirrhosis in anti-HCV-positive long-term haemodialysis patients. Nephrol Dial Transplant 16 8 (2001) 1669-1674
26. Wolfe R.A., Ashby V.B., Milford E.L., et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 341 23 (1999) 1725-1730
27. Bloom R.D., Sayer G., Fa K., et al. Outcome of hepatitis C virus-infected kidney transplant candidates who remain on the waiting list. Am J Transplant 5 1 (2005) 139-144
28. Sezer S., Ozdemir F.N., Akcay A., et al. Renal transplantation offers a better survival in HCV-infected ESRD patients. Clin Transplant 18 5 (2004) 619-623
29. Knoll G.A., Tankersley M.R., Lee J.Y., et al. The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients. Am J Kidney Dis 29 4 (1997) 608-614
30. Lau J.Y., Davis G.L., Brunson M.E., et al. Hepatitis C virus infection in kidney transplant recipients. Hepatology 18 5 (1993) 1027-1031
31. Orloff S.L., Stempel C.A., Wright T.L., et al. Long-term outcome in kidney transplant patients with hepatitis C (HCV) infection. Clin Transplant 9 2 (1995) 119-124
32. Lee W.C., Shu K.H., Cheng C.H., et al. Long-term impact of hepatitis B, C virus infection on renal transplantation. Am J Nephrol 21 4 (2001) 300-306
33. Stempel C.A., Lake J., Kuo G., et al. Hepatitis C-its prevalence in end-stage renal failure patients and clinical course after kidney transplantation. Transplantation 55 2 (1993) 273-276
34. Periera B.J., Wright T.L., Schmid C.H., et al. The impact of pretransplantation hepatitis C infection on the outcome of renal transplantation. Transplantation 60 8 (1995) 799-805
35. Legendre C., Garrigue V., Le Bihan C., et al. Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients. Transplantation 65 5 (1998) 667-670
36. Hanafusa T., Ichikawa Y., Kishikawa H., et al. Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years. Transplantation 66 4 (1998) 471-476
37. Fabrizi F., Martin P., Dixit V., et al. Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies. Am J Transplant 5 10 (2005) 2433-2440
38. Lunel F., Cadranel J.F., Rosenheim M., et al. Hepatitis virus infections in heart transplant recipients: epidemiology, natural history, characteristics, and impact on survival. Gastroenterology 119 4 (2000) 1064-1074
39. Delladetsima I., Psichogiou M., Sypsa V., et al. The course of hepatitis C virus infection in pretransplantation anti-hepatitis C virus-negative renal transplant recipients: a retrospective follow-up study. Am J Kidney Dis 47 2 (2006) 309-316
40. Sypsa V., Touloumi G., Tassopoulos N.C., et al. Reconstructing and predicting the hepatitis C virus epidemic in Greece: increasing trends of cirrhosis and hepatocellular carcinoma despite the decline in incidence of HCV infection. J Viral Hepat 11 4 (2004) 366-374
41. Delgado J., Munoz de Bustillo E., Ibarrola C., et al. Hepatitis C virus-related fibrosing cholestatic hepatitis after cardiac transplantation: is azathioprine a contributory factor?. J Heart Lung Transplant 18 6 (1999) 607-610
42. Yildiz A., Tutuncu Y., Yazici H., et al. Association between hepatitis C virus infection and development of posttransplantation diabetes mellitus in renal transplant recipients. Transplantation 74 8 (2002) 1109-1113
43. Bloom R.D., Rao V., Weng F., et al. Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol 13 5 (2002) 1374-1380
44. Bloom R.D., and Doyle A.M. Kidney disease after heart and lung transplantation. Am J Transplant 6 4 (2006) 671-679
45. Cruzado J.M., Carrera M., Torras J., et al. Hepatitis C virus infection and de novo glomerular lesions in renal allografts. Am J Transplant 1 2 (2001) 171-178
46. Cruzado J.M., Gil-Vernet S., Ercilla G., et al. Hepatitis C virus-associated membranoproliferative glomerulonephritis in renal allografts. J Am Soc Nephrol 7 11 (1996) 2469-2475
47. van Duijnhoven E.M., Christiaans M.H., Boots J.M., et al. Glucose metabolism in the first 3 years after renal transplantation in patients receiving tacrolimus versus cyclosporine-based immunosuppression. J Am Soc Nephrol 13 1 (2002) 213-220
48. Cruzado J.M., Casanovas-Taltavull T., Torras J., et al. Pretransplant interferon prevents hepatitis C virus-associated glomerulonephritis in renal allografts by HCV-RNA clearance. Am J Transplant 3 3 (2003) 357-360
49. Kamar N., Toupance O., Buchler M., et al. Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol 14 8 (2003) 2092-2098
50. Huraib S., Iqbal A., Tanimu D., et al. Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. Am J Nephrol 21 6 (2001) 435-440
51. Rostaing L., Izopet J., Baron E., et al. Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. Transplantation 59 10 (1995) 1426-1431
52. Fabrizi F., Martin P., and Bunnapradist S. Treatment of chronic viral hepatitis in patients with renal disease. Gastroenterol Clin North Am 33 3 (2004) 655-670
53. Rostaing L., Chatelut E., Payen J.L., et al. Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. J Am Soc Nephrol 9 12 (1998) 2344-2348
54. Tan A.C., Brouwer J.T., Glue P., et al. Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study. Nephrol Dial Transplant 16 1 (2001) 193-195
55. Bruchfeld A., Stahle L., Andersson J., et al. Interferon and ribavirin therapy in dialysis patients with chronic hepatitis C. Nephrol Dial Transplant 16 8 (2001) 1729
56. Russo M.W., Ghalib R., Sigal S., et al. Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant 21 2 (2006) 437-443
57. Bruchfeld AJ. Viral Hepatitis. 2006;13(5):316-21.
58. Casanovas-Taltavull T., Baliellas C., Benasco C., et al. Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: results after transplantation. Am J Gastroenterol 96 4 (2001) 1170-1177
59. Tang S., Cheng I.K., Leung V.K., et al. Successful treatment of hepatitis C after kidney transplantation with combined interferon alpha-2b and ribavirin. J Hepatol 39 5 (2003) 875-878
60. Kamar N., Sandres-Saune K., Selves J., et al. Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology. Am J Kidney Dis 42 1 (2003) 184-192
61. Casanovas Taltavull T., Baliellas C., Sese E., et al. Interferon may be useful in hemodialysis patients with hepatitis C virus chronic infection who are candidates for kidney transplant. Transplant Proc 27 4 (1995) 2229-2230
62. Benci A., Caremani M., Menchetti D., et al. Low-dose leukocyte interferon-alpha therapy in dialysed patients with chronic hepatitis C. Curr Med Res Opin 14 3 (1998) 141-144
63. Campistol J.M., Esforzado N., Martinez J., et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrol Dial Transplant 14 11 (1999) 2704-2709
64. Shu K.H., Lan J.L., Wu M.J., et al. Ultralow-dose alpha-interferon plus ribavirin for the treatment of active hepatitis C in renal transplant recipients. Transplantation 77 12 (2004) 1894-1896
65. Fontaine H., Vallet-Pichard A., Equi-Andrade C., et al. Histopathologic efficacy of ribavirin monotherapy in kidney allograft recipients with chronic hepatitis C. Transplantation 78 6 (2004) 853-857
66. Durlik M., Gaciong Z., Rancewicz Z., et al. Renal allograft function in patients with chronic viral hepatitis B and C treated with interferon alpha. Transplant Proc 27 1 (1995) 958-959
67. Therret E., Pol S., Legendre C., et al. Low-dose recombinant leukocyte interferon-alpha treatment of hepatitis C viral infection in renal transplant recipients. A pilot study. Transplantation 58 5 (1994) 625-628
68. Tokumoto T., Tanabe K., Sonda K., et al. Effect of interferon (IFN-alpha) for prevention of hepatitis C transmission from a seropositive donor to a seronegative recipient in renal transplantation. Transplant Proc 28 3 (1996) 1503-1504